November 11, 2000 Trade Star Pharmaceutical Co., Ltd was founded.


2003 More than a dozen products distributed by Trade Star were sold in military hospitals nationwide, with Cefuroxime leading the way. In addition, sales network in Hebei and Tianjin was established. Trade Star entered the market with a strong momentum.


The beginning of 2003 Thymopentin for Injection distributed by Trade Star made prominent contributions to stabilize(mitigate) the conditions of patients during the SARS outbreak in Beijing.


2004 Thymopathy for Injection distributed by Trade Star covered the majority of domestic market with sales volume of over 100 million RMB, representing a remarkable achievement.


October, 2004 George Lee, Chairman of Trade Star, was appointed as the director of Society of Infectious Diseases, CMA


August, 2005 “Thymopentin for Injection”, applied by Trade Star, entrusted to Beijing SL Pharmaceutical Co., Ltd for production, was approved by the government and the sales volume exceeded 100 million in that year.


April, 2006 Monosialotetrahexosyl Ganglioside Sodium for Injection, jointly researched and developed by Trade Star, was approved.


May, 2006 Cefdinir Dispersible Tablets jointly developed by Trade Star formally entered into service.


June, 2006 Trade Star was recognized as Beijing High-tech Enterprise.


July, 2007 George Lee, Chairman of Trade Star, was appointed as the director of Beijing Pharmacist Association.


February 4, 2009 Beijing Trade Star Medicine Biological Technology Co., Ltd was founded.


May 1, 2009 Trade Star Investment Holding Group (S) Pte., Ltd was founded.


May 21, 2009 Trade Star (Beijing) International Investment Co., Ltd was founded.


June 30, 2009 Trade Star (Beijing) International Investment Co., Ltd and Trade Star (Beijing) Medicine Biological Technology were respectively rated as Zhongguancun High-tech Enterprise and passed the audits again in 2011.


August, 2009 Trade Star moved to an independent building in Advanced Business Park—— a business center located in the south west of Beijing.


2009 The sales volume of Monosialotetrahexosylganglioside Sodium for Injection ranked second in China.


2010 The market share and sales volume of Cefdinir Dispersible Tablet, distributed exclusively by Trade Star, ranked first in domestic Level II and above hospitals.


February 5, 2010 Trade Star International Medicine Co., Ltd (Hongkong) was founded.


Sep , 2010 Vancomycin Hydrochloride for Injection produced by Zhengjiang Haizheng Pharmaceutical Co., Ltd was distributed exclusively by Trade Star.


February, 2011 Cefazedone Sodium for Injection produced by Xin Feng Pharmaceutical Co., Ltd, Korea was exclusively imported by Trade Star for domestic sales.


January, 2012 George Lee, Chairman of Trade Star, was appointed as Director of China Pharmaceutical Enterprise Management Association.


March, 2012 Trade Star acquired 100% of Chengchuangkangyun (Beijing) Medicine Technology Co., Ltd, representing the R&D Department of Trade Star was formally established.


May, 2013 Trade Star made a successful acquisition of Jinyanglikang (Beijing) Medicine Co., Ltd, representing a whole industry chain of pharmaceutical business has been set up.


July 31, 2013 A formal announcement was made that a group training and holiday center would be built in Ji County, a place of scenic beauty in Tianjin, and that 20 acres of land had been expropriated.


March, 2014 Beijing Zhongzhi Medical Technology Co., Ltd’s incorporation in Petrochemical New Material Science and Technology Industry Base in Yanshan, Beijing marked the industry chain of Trade Star Holding Group has become fully interconnected.


March 16, 2014 Trade Star’s engineering project in Petrochemical New Material Science and Technology Industry Base in Yanshan, Beijing was officially commenced. It would serve as a modern logistics center with GSP authentication. The first phase of the construction is due for completion in June, 2014.


June 6, 2014 Trade Star signed Pharmaceutical Factory Capital Increase and Share Expansion Cooperation Agreement with Yunnan No.1 Fuel Plant. Trade Star went through with the merger of Yunnan Yongan Pharmaceutical Co. Ltd, symbolizing a solid step towards the medical industry field.


June 27, 2014 Ademetionine 1,4-butanedisulfonate for Injection was approved, in which Trade Star plays a predominant role in R&D.


July 24, 2014 The product release conference of “Ademetionine 1,4-butanedisulfonate for Injection” held in Kunming, Yunnan marked its access to market.


August 26, 2014 Beijing Jinyang Likang Medicine Co., Ltd passed the audit for Good Supply Practice (GSP), and gained the new GSP Certificate.


July 16, 2015 Yunnan Yongan Pharmaceutical Co., Ltd, a subsidiary of Trade Star Pharmaceutical Holding Group Co., Ltd, obtained the new GMP Certificate.


June 12, 2016 Trade Star acquired 100% of Xizang Jianlian Medicine Co., Ltd, symbolizing a breakthrough in the field of pharmaceutical business.


July 4, 2016 Trade Star purchased 100% of Nanjing Meirui Pharmaceutical Co., Ltd from GSK, which embodies a further improvement in pharmaceutical industry.


July, 2017 Qiuxieling Granules was recognized as “gold brick product” with the best market potential for the treatment of pediatric disease.


December, 2017 Trade Star became an organization member of CPA, and George Lee became a member of CPA.


August 17, 2017 Keanrui Pharmaceutical Technology Co., Ltd, a subsidiary of Trade Star, set up a branch office in Tokyo, manifesting Trade Star’s access to international market.


June 12, 2019 The foundation stone laying ceremony of Beijing Zhongzhi Medical Technology Co., Ltd was held. It would be the new headquarter of Trade Star, functioning as administration center, marketing management center, commercial operation center, pilot scale test base for R&D and staff recreational base. It would be the third pharmaceutical development park of Trade Star, succeeded by Nanjing Meirui and Yongan Pharmaceutical Co. Ltd


October 8, 2019 Keanrui Pharmaceuticals, INC.’s incorporation in Massachusetts, USA, marked the expansion of overseas business.